Efficacy of Oral Eplerenone for the Treatment of Chronic Central Serous
Keywords:Chronic central serous retinopathy, Sub retinal fluid height, Sub retinal fluid diameter, Central macular thickness, Oral Eplerenone
Background: Central serous chorioretinopathy is a sight threatening disease characterized by accumulation of serous sub retinal fluid occurs due to serous detachment of neurosensory retina and retinal pigment epithelium.Purpose: To evaluate the efficacy of oral Eplerenone in patients with chronic CSCR. Methods: In a tertiary care hospital, a prospective analysis of all the patients with chronic CSCR treated with oral Eplerenone who had been seen for at least three months were prospectively analyzed in a tertiary care hospital. Changes in CMT as measured by spectral-domain OCT served as the primary outcome. Changes in BCVA as measured by log MAR and the number of patients obtaining full resolution of SRF served as the secondary outcomes.Results: In 25 patients (15M /10F) treated with 25mg and 50mg of oral Eplerenone were included. The mean age of follow up was 21±17.6 wks. Mean CMT decreased from 401±133 to 317±75μm at 6 wks& to 285±68μm at 3 months. Mean height of SRF decreased from 157±113 to 78±89μm at 6 wks& to 51±79μm at 3 months. Complete resolution of SRF was found in 15 pts after 3 months. BCVA (log MAR) improved from 0.2±0.18 to 0.14±0.16 at 6 wks & to 0.07±0.13 in 3 months.
Conclusion: Eplerenone therapy may improve BCVA & decrease CMT and SRF height in pts with chronic CSCR.
How to Cite
Copyright (c) 2023 Anand Sharan, Randhir Kumar, Asif Sahnawaz, Kumari Preeti, Archana Sinha
This work is licensed under a Creative Commons Attribution 4.0 International License.